KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cost of Revenue: 2011-2024

Historic Cost of Revenue for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Dec 2024 value amounting to $1.5 billion.

  • Vertex Pharmaceuticals' Cost of Revenue rose 5.65% to $414.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 9.06%. This contributed to the annual value of $1.5 billion for FY2024, which is 21.26% up from last year.
  • Vertex Pharmaceuticals' Cost of Revenue amounted to $1.5 billion in FY2024, which was up 21.26% from $1.3 billion recorded in FY2023.
  • Vertex Pharmaceuticals' 5-year Cost of Revenue high stood at $1.5 billion for FY2024, and its period low was $736.3 million during FY2020.
  • In the last 3 years, Vertex Pharmaceuticals' Cost of Revenue had a median value of $1.3 billion in 2023 and averaged $1.3 billion.
  • Data for Vertex Pharmaceuticals' Cost of Revenue shows a peak YoY skyrocketed of 34.41% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Vertex Pharmaceuticals' Cost of Revenue stood at $736.3 million in 2020, then rose by 22.80% to $904.2 million in 2021, then climbed by 19.48% to $1.1 billion in 2022, then climbed by 16.84% to $1.3 billion in 2023, then climbed by 21.26% to $1.5 billion in 2024.